Clinical significance of targeting glioma with Ibrutinib

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100047687

Enrollment

Unknown

Registered

2021-06-21

Start date

2021-10-18

Completion date

Unknown

Last updated

2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glioma

Interventions

case group:Nil

Eligibility

Sex/Gender

All

Age

1 Years to 100 Years

Inclusion criteria

Inclusion criteria: More than 2 pathologists re-read the pictures together and confirmed the diagnosis as malignant glioma.

Exclusion criteria

Exclusion criteria: Cases with undetermined tumor grade and uncertain diagnosis.

Design outcomes

Primary

Measure	Time frame
Immunohistochemical indicators(MGMT/Ki67/Olig2/Syn/GFAP/IDH1/ATRX);	—

Secondary

Measure	Time frame
Tumor infiltrating immune cell marker and its activation level(CCR2/CD163/ITGA4/LY6C/CD45/CD11b/CD86/PD-1/CTLA-4) ;Expression of BTK family in tumor cells and immune cells (BTK/BMX/ITK);	—

Countries

China

Contacts

Public ContactShi Yu

the First Affiliated Hospital of Army Medical University, PLA

drshiyu@126.com+86 13512350865

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026